請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62206
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊家榮 | |
dc.contributor.author | I-Ni Hsieh | en |
dc.contributor.author | 謝伊妮 | zh_TW |
dc.date.accessioned | 2021-06-16T13:33:47Z | - |
dc.date.available | 2016-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-18 | |
dc.identifier.citation | 1. Vojinovic J, Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Molecular Medicine. 2011;17:397-403.
2. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. The Journal of Rheumatology. 2004;31:2071-5. 3. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998-1006. 4. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Kuster RM, Michels H, Moebius D, Rogalski B, Thon A; Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 2004;63:1638-44. 5. Papagoras C, Voulgari PV, Drosos AA. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmunity Reviews. 2010;9:574-82. 6. Ernest HS, Gabriel S. Cytokine pathways and joint inflammation in rheumatoid arthritis. The New England Journal of Medicine. 2001;12:907-16. 7. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs: the impact of poor function and functional decline. Arthritis and Rheumatism. 1999;42:1209-18. 8. McIntosh E. The cost of rheumatoid arthritis. British Journal of Rheumatology. 1996;35:781-90. 9. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 american college of rheumatology criteria: a systematic review. Seminars in Arthritis and Rheumatism. 2006;36:182-8. 10. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-11. 11. Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs. 2005;65:473-96. 12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. Rheumatoid arthritis classification criteria. Annals of the Rheumatic Disease. 2010;69:1580-8. 13. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis and Rheumatism. 2000;43:30-7. 14. Kochi Y, Suzuki A, Yamada R, Yamamoto K. Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis. Nature Reviews Rheumatology. 2010;6:290-5. 15. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. New England Journal of Medicine. 2004;350:2591-602. 16. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery. 2003;2:473-88. 17. Klinkhoff A. Biological agents for rheumatoid arthritis - Targeting both physical function and structural damage. Drugs. 2004; 64:1267-83. 18. Olsen NJ, Stein CM. Drug therapy - New drugs for rheumatoid arthritis. New England Journal of Medicine. 2004;350:2167-79. 19. Kerstin Klein and Steffen Gay. Epigenetic modifications in rheumatoid arthritis, a review. Current Opinion in Pharmacology. 2013;DOI:10.1016/j.coph.2013.01.007. 20. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. The Biochemical Journal. 2003;370:737-49. 21. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends in Immunology. 2011;32:335-43. 22. Reichert N, Choukrallah MA, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cellular and Molecular Life Sciences. 2012;69:2173-87. 23. Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K, Kadota Y, Inagaki J, Hirohata S, Ninomiya Y, Makino H. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Research & Therapy. 2010;12:R133. 24. Villagra A, Sotomayor EM, Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene. 2010;29:157-73. 25. Vojinovic J, Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Molecular Medicine. 2011;17:397-403. 26. Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic. 2002;3:388-96. 27. Hirsch C, Ploegh HL. Intracellular targeting of the proteasome. Trends in Cell Biology. 2000;10:268-72. 28. Wickner S, Maurizi MR, Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. Science. 1999;286:1888-93. 29. Hideshima T, Richardson PG, Anderson KC. Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma. Molecular Cancer Therapeutics. 2011;10:2034-42. 30. Sweeney SE, Firestein GS: Medicine in focus Rheumatoid Arthritis: regulation of synovial inflammation. The International Journal of Biochemistry&Cell Biology. 2004;36:372-8. 31. Firestein GS. Evolving concepts of rheumatoid arthristis. Nature. 2003;423:356-61. 32. Han Z, Boyle DL, Manning AM, Firestein GS: AP-1 and NF-kB regulation in rheumatoid arthristis and murine collagen-induced arthritis. Autoimmunity. 1998;28:197-208. 33. Szekanecz Z, Koch AE. Update on synovitis. Current Rheumatology Reports 2001;3:53-63. 34. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. Annual Review Immunology. 1994;12:141-79. 35. Karin M, Ben-Neriah Y. Phosphorylation Meets Ubiquitination: The Control of NF-kB Activity. Annual Review Immunology. 2000;18:621-63. 36. Lin AW, Chang CC, McCormick CC. Molecular cloning and expression of an avian macrophage nitric-oxide synthase cDNA and the analysis of the genomic 5’-flanking region. The Journal of Biological Chemistry. 1996;271:11911-9. 37. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclooxygenase-2 gene. The Biochemical Journal. 1994;302:723-7. 38. Miyamoto I, Liu J, Shimizu K, Sato M, Kukita A, Kukita T, Kondo R. Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum. European Journal of Pharmacology. 2009;602:1-7. 39. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappa B/p65 DNA binding. Molecular Cancer Research. 2005;3:100-9. 40. Perkins ND. Integrating cell-signalling pathways with NF-kappa B and IKK function. Nature Reviews Molecular Cell Biology. 2007;8:49-62. 41. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappa B by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Research. 2006;66:5409-18. 42. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. Journal of Biological Chemistry. 2001; 276:44641-6. 43. Kim YK, Lee EK, Kang JK, Kim JA, You JS, Park JH, Seo DW, Hwang JW, Kim SN, Lee HY, Lee HW, Han JW. Activation of NF-kappa B by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death and Differentiation. 2006;13:2033-41. 44. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of infl ammatory diseases? Drug Discov Today. 2005;10:197-204. 45. Hancock WW, Akimova T, Beier UH, Liu Y, Wang L. HDAC inhibitor therapy in autoimmunity and transplantation. Annals of the Rheumatic Diseases. 2012;71:i46-54. 46. Zafonte BT, Hulit J, Amanatullah DF, Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP, Pestell RG. Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Frontiers in Bioscience. 2000;5: d938-961. 47. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nature Reviews Molecular Cell Biology. 2006;7:667-77. 48. Rudolph J. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nature Reviews Cancer. 2007;7:202-11. 49. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Research. 2001;61:6234-8. 50. Sherr CJ. The INK4a/ARF network in tumour suppression. Nature Reviews Molecular Cell Biology. 2001;2:731-7. 51. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. Journal of Immunology. 2003;171:4913-9. 52. Hume DA, Fairlie DP. Therapeutic targets in inflammatory disease. Current Medicinal Chemistry. 2005;12:2925-9. 53. Ku CS, Pham TX, Park Y, Kim B, Shin MS, Kang I, Lee J. Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-kB pathway in macrophages and splenocytes. Biochimica et Biophysica Acta 2013;1830:2981-8. 54. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Annals of the Rheumatic Diseases. 2012;71:424-31. 55. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N, Yoshida A, Hirohata S, Ohtsuka A, Ozaki T. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage. 2008;16:723-32. 56. Inoue K, Kobayashi M, Yano K, Miura M, Izumi A, Mataki C, Doi T, Hamakubo T, Reid PC, Hume DA, Yoshida M, Aird WC, Kodama T, Minami T. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arteriosclerosis, Thrombosis and Vascular Biology. 2006;26:2652-9. 57. Pham L, Kaiser B, Romsa A, Schwarz T, Gopalakrishnan R, Jensen ED, Mansky KC. HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. The Journal of Biological Chemistry. 2011;286:12056-65. 58. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P, Hancock WW. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Molecular and Cellular Biology. 2011;31:2066-78. 59. Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, Le GT, Lucke AJ, Holding CA, Haynes DR. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. Journal of Cellular Physiology. 2011;226:3233-41. 60. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer. 2001;1:194-202. 61. Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington’s disease. PLoS One. 2011;6:e27746. 62. Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM, Kim HS. Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in Tamoxifen-Resistant MCF-7 Breast Cancer Cells. International Journal of Medical Sciences. 2012;9:881-93. 63. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Molecular Cancer Therapeutics. 2011;10:2034-42. 64. Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, Sakamoto KM. The aggresome pathway as a target for therapy in hematologic malignancies. Molecular Genetics and Metabolism. 2008;94:283-6. 65. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007;26:5468-76 66. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-61. 67. Rudolph J. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nature Reviews Cancer. 2007;7:202-11. 68. Li L, Dai HJ, Ye M, Wang SL, Xiao XJ, Zheng J, Chen HY, Luo YH, Liu J. Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer Cell International. 2012;23:49. 69. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA, Dannenberg JH. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. The EMBO Journal. 2010;29:2586-97. 70. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nature Reviews Rheumatology. 2012;8:656-64. 71. Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. European Journal of Pharmacology. 2009;623:22-9. 72. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-kappaB Activation. The Journal of Biological Chemistry. 2006;281:5612-22. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62206 | - |
dc.description.abstract | 實驗目的:類風溼性關節炎是一種全身性的自體免疫疾病,其病理方面包括滑液
膜細胞的增生、發炎物質的表現及免疫細胞的持續性浸潤,而這些現象可能源自 於HDAC (組蛋白去乙醯酶)對於表觀遺傳調控的異常;因此,HDAC 抑制劑未來 可能可以用來治療發炎性疾病。此篇論文的研究目的為探討一個新型的HDAC 抑 制劑MPT0G009 在類風溼性關節炎滑液膜細胞以及實驗動物模型中的抗風溼效果 及其機轉。 實驗方法:利用HDAC assay kit 測定HDAC 抑制劑對於各種HDAC 亞型的抑制活性能力,並利用西方點墨法觀察HDAC 抑制劑是否會影響各種HDAC 亞型的蛋白 質表現;利用SRB 試驗測定藥物對於細胞增生的抑制效果,並利用流式細胞儀探 討藥物對於細胞週期的影響及機轉;發炎反應中的細胞激素則是用ELISA (酵素免 疫分析法)測定;利用酒石酸具耐受性酸性磷酸酵素染色法觀察噬骨細胞的生成分 化以及型態,並利用流式細胞儀檢測噬骨細胞生物標記的表現量。另外,我們也 於實驗中將細胞過量表現HDAC 來探討藥物的抗發炎及抑制噬骨細胞生成的效果 是否直接透過抑制HDAC。我們更利用動物實驗模型來驗證藥物的抗風溼效果與 機轉。 實驗結果:MPT0G009 相較於已核准上市的其中一種HDAC 抑制劑,SAHA,具 有更強的HDAC 活性抑制能力,並且在類風溼性關節炎滑液膜細胞中能夠抑制 HDAC3 的蛋白質表現。在類風溼性關節炎滑液膜細胞與巨噬細胞中,MPT0G009 均顯示出很好的抗發炎效果,並且可以抑制滑液膜細胞增生。另外,在利用巨噬 細胞分化成噬骨細胞的實驗中,我們發現MPT0G009 在3 nM 的濃度下能有效抑制 噬骨細胞生成,而SAHA 在30 nM 下卻無法有明顯的抑制效果。在動物實驗中, 我們發現MPT0G009 在25 mg/kg 的口服給予下,能達到與SAHA 在200 mg/kg 給予下相似的抗風溼效果。 結論:我們的體內與體外實驗結果顯示MPT0G009 具有很強的抗發炎、抑制滑液 膜細胞增生、抑制噬骨細胞生成及減少硬骨與軟骨損壞的效果,迄今尚未有HDAC 抑制劑被核准上市或是進入臨床試驗來治療類風濕性關節炎,因此MPT0G009 可 望在未來能發展成為治療類風濕性關節炎的藥物。 | zh_TW |
dc.description.abstract | Objective. The pathology of rheumatoid arthritis (RA) includes synoviocytes proliferation, expression of inflammatory mediators, and persistent recruitment of
immune cell, and these might result from dysregulation of epigenetic control by histone deacetylase (HDAC). Therefore, HDAC inhibitor may act as a new treatment for inflammatory disease. The aim of this study is to examine the anti-arthritic effect of MPT0G009, a histone deacetylse (HDAC) inhibitor, by in vitro and in vivo models. Methods. HDACs activity and protein expression were determined by HDAC assay kit and western blot. Anti-proliferative effect was determined by SRB assay, and the cell cycle arrest was determined by flow cytometry. Cytokines production was studied by ELISA. Osteoclastogenesis was evaluated by TRAP stain and flow cytometry. In vivo study was determined by Adjuvant Induced Arthritis rat model and IHC stain. Result. The IC50 values of MPT0G009 against enzymatic activity of HDACs were significantly lower than SAHA, and MPT0G009 could inhibit HDAC3 protein expression in RA synovial fibroblasts, indicating that MPT0G009 is more potent than SAHA. Treatment of RAW264.7 macrophages and RA synovial fibroblasts with MPT0G009 inhibited cytokines secretion in a concentration-dependent manner, and MPT0G009 also had anti-proliferative effect on RA synovial fibroblasts. In addition, MPT0G009 dramatically suppressed RANKL/M-CSF induced osteoclastogenesis from macrophages at low concentration (3 nM). The in vivo anti-arthritic effects of MPT0G009 were evaluated in a Mycobacterium butyricum-induced arthritis model in rats. Oral administration of MPT0G009 (25 mg/kg) significantly inhibited paw swelling,bone destruction and reduced serum cytokine levels. Conclusion. Our results demonstrate that HDAC inhibitor MPT0G009 inhibits the development of arthritis, suggesting that it might provide a new therapeutic approach to inflammatory arthritis diseases. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:33:47Z (GMT). No. of bitstreams: 1 ntu-102-R00423011-1.pdf: 9552601 bytes, checksum: 94cdedd74f03873ec87c51fb0bc67544 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 縮寫表----------------II
中文摘要-------------III 英文摘要--------------V 第一章 研究動機與目的----1 第二章 文獻回顧---------3 第三章 實驗材料與方法---24 第一節 實驗材料--------24 第二節 實驗方法--------26 第四章 實驗結果--------36 第五章 討論-----------42 第六章 結論與展望-------47 參考文獻---------------74 | |
dc.language.iso | zh-TW | |
dc.title | 新型組蛋白去乙醯酶抑制劑在類風濕性關節炎之功能與機轉探討 | zh_TW |
dc.title | Functional and Mechanistic Studies of A Novel Histone
Deacetylase Inhibitor in Rheumatoid Arthritis | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 顧記華,蕭哲志,潘秀玲 | |
dc.subject.keyword | 類風溼性關節炎,組蛋白去乙醯酶,表觀遺傳調控,滑液膜細胞,噬骨細胞, | zh_TW |
dc.subject.keyword | Rheumatoid arthritis,Histone deacetylase,Epigenetic regulation,synovial fibrolasts,osteoclasts, | en |
dc.relation.page | 81 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-07-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 9.33 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。